365 related articles for article (PubMed ID: 7548198)
1. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway.
Levade T; Vidal F; Vermeersch S; Andrieu N; Gatt S; Salvayre R
Biochim Biophys Acta; 1995 Oct; 1258(3):277-87. PubMed ID: 7548198
[TBL] [Abstract][Full Text] [Related]
2. Uptake and degradation of several pyrenesphingomyelins by skin fibroblasts from control subjects and patients with Niemann-Pick disease. Effect of the structure of the fluorescent fatty acyl residue.
Levade T; Gatt S; Salvayre R
Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):211-7. PubMed ID: 2018477
[TBL] [Abstract][Full Text] [Related]
3. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase.
Levade T; Gatt S; Maret A; Salvayre R
J Biol Chem; 1991 Jul; 266(21):13519-29. PubMed ID: 1649823
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal involvement in cellular turnover of plasma membrane sphingomyelin.
Sutrina SL; Chen WW
Biochim Biophys Acta; 1984 Apr; 793(2):169-79. PubMed ID: 6424713
[TBL] [Abstract][Full Text] [Related]
5. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells.
Graber D; Salvayre R; Levade T
J Neurochem; 1994 Sep; 63(3):1060-8. PubMed ID: 8051547
[TBL] [Abstract][Full Text] [Related]
6. Uptake and intracellular degradation of fluorescent sphingomyelin by fibroblasts from normal individuals and a patient with Niemann-Pick disease.
Levade T; Gatt S
Biochim Biophys Acta; 1987 Apr; 918(3):250-9. PubMed ID: 3567213
[TBL] [Abstract][Full Text] [Related]
7. The role of sphingomyelin in phosphatidylcholine metabolism in cultured human fibroblasts from control and sphingomyelin lipidosis patients and in Chinese hamster ovary cells.
Spence MW; Cook HW; Byers DM; Palmer FB
Biochem J; 1990 Jun; 268(3):719-24. PubMed ID: 2363706
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of pyrenesulfonylamido-sphingomyelin and its use as substrate for determining sphingomyelinase activity and diagnosing Niemann-Pick disease.
Klar R; Levade T; Gatt S
Clin Chim Acta; 1988 Sep; 176(3):259-67. PubMed ID: 2846208
[TBL] [Abstract][Full Text] [Related]
9. Uptake and metabolism of radioactively labeled sphingomyelin in cultured skin fibroblasts from controls and patients with Niemann-Pick disease and other lysosomal storage diseases.
Kudoh T; Velkoff MA; Wenger DA
Biochim Biophys Acta; 1983 Nov; 754(1):82-92. PubMed ID: 6626569
[TBL] [Abstract][Full Text] [Related]
10. Niemann-Pick type II fibroblasts exhibit impaired cholesterol esterification in response to sphingomyelin hydrolysis.
Byers DM; Morgan MW; Cook HW; Palmer FB; Spence MW
Biochim Biophys Acta; 1992 Jan; 1138(1):20-6. PubMed ID: 1737066
[TBL] [Abstract][Full Text] [Related]
11. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.
Darroch PI; Dagan A; Granot T; He X; Gatt S; Schuchman EH
J Lipid Res; 2005 Nov; 46(11):2315-24. PubMed ID: 16150832
[TBL] [Abstract][Full Text] [Related]
12. Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-Ketocholesterol.
Maor I; Mandel H; Aviram M
Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1378-87. PubMed ID: 7670952
[TBL] [Abstract][Full Text] [Related]
13. Pathways of sphingomyelin metabolism in cultured fibroblasts from normal and sphingomyelin lipidosis subjects.
Spence MW; Clarke JT; Cook HW
J Biol Chem; 1983 Jul; 258(14):8595-600. PubMed ID: 6863302
[TBL] [Abstract][Full Text] [Related]
14. Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation.
Christomanou H
Hoppe Seylers Z Physiol Chem; 1980 Oct; 361(10):1489-502. PubMed ID: 6256275
[TBL] [Abstract][Full Text] [Related]
15. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells.
Suchi M; Dinur T; Desnick RJ; Gatt S; Pereira L; Gilboa E; Schuchman EH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3227-31. PubMed ID: 1565614
[TBL] [Abstract][Full Text] [Related]
16. Evidence against involvement of the acid lysosomal sphingomyelinase in the tumor-necrosis-factor- and interleukin-1-induced sphingomyelin cycle and cell proliferation in human fibroblasts.
Andrieu N; Salvayre R; Levade T
Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):341-5. PubMed ID: 7980390
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of sphingomyelin in cultured skin fibroblasts from patients with different types of Niemann-Pick disease.
Nakashima M; Kudoh T; Sukegawa K; Maruyama K; Orii T
Tohoku J Exp Med; 1986 Apr; 148(4):365-71. PubMed ID: 3738903
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of Niemann-Pick disease using a simple and sensitive fluorimetric assay of sphingomyelinase activity.
Besley GT
Clin Chim Acta; 1978 Dec; 90(3):269-78. PubMed ID: 31994
[TBL] [Abstract][Full Text] [Related]
19. Sphingomyelinases and Niemann-Pick disease.
Levade T; Salvayre R; Douste-Blazy L
J Clin Chem Clin Biochem; 1986 Apr; 24(4):205-20. PubMed ID: 3009683
[TBL] [Abstract][Full Text] [Related]
20. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E
Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
